TABLE 1.
Baseline participant demographic and clinical data1
| Variable | All participants (N = 42) |
|---|---|
| Age, y | 60.4 ± 5.4 |
| SBP, mmHg | 119.8 ± 16.0 |
| DBP, mmHg | 72.3 ± 9.3 |
| Heart rate | 68.1 ± 9.3 |
| BMI, kg/m2 | 27.1 (25.2–28.3) |
| Waist circumference, cm | 98.0 ± 8.1 |
| Current smoker | 3 (7.1) |
| Former smoker | 23 (54.7) |
| Hypertension | 21 (50.0) |
| Dyslipidemia | 18 (42.9) |
| Physical activity | 23 (53.8) |
| 5–10 METs.h/wk | 7 (30.4) |
| 10–40 METs.h/wk | 10 (43.5) |
| >40 METs.h/wk | 6 (26.1) |
| Physical inactivity | 19 (45.2) |
| History of myocardial infarction | 28 (66.7) |
| >50% stenosis of epicardial artery | 25 (59.5) |
| CABG | 13 (31.0) |
| PCI | 19 (45.2) |
| Medications | |
| β-Blockers | 30 (71.4) |
| ACE inhibitors | 21 (50.0) |
| ARBs | 10 (23.8) |
| CCBs | 3 (7.1) |
| Aspirin | 37 (88.1) |
| Clopidogrel | 10 (23.8) |
| Statins | 38 (90.5) |
| PPIs | 8 (19.0) |
| Diuretics | |
| Total cholesterol, mg/dL | 143 (127–170) |
| High-density lipoprotein, mg/dL | 46 (39–54) |
| Low-density lipoprotein, mg/dL | 77 (66–97) |
| Triglycerides, mg/dL | 85 (66–111) |
| Apolipoprotein A, g/L | 1.37 (1.22–1.51) |
| Apolipoprotein B, g/L | 0.7 (0.62–0.86) |
| Lipoprotein a, mg/dL | 60.5 (4.3–91.3) |
| Fasting glucose, mg/dL | 90 (86–100) |
| GFR, mL/min/1.73 m2 | 85.5 (72–99) |
| hsCRP, mg/L | 1.01 (0.58–2.77) |
| IL-6, pg/mL | 0.75 (0–4.8) |
| LPS, EU/mL | 0.76 (0.63–0.81) |
1
Data are presented as the mean ± SD, median (interquartile range), or n (%). ACE, angiotensin-converting enzyme; ARBs, angiotensin-receptor blockers; CABG, previous coronary artery bypass grafting; CCBs, calcium channel blockers; DBP, diastolic blood pressure; GFR, glomerular filtration rate; hsCRP, high-sensitivity C-reactive protein; LPS, lipopolysaccharides; METs, metabolic equivalents; METs.h/wk, METs-h/wk score = (MET level × hours × times/wk); PCI, previous percutaneous coronary intervention; PPIs, proton pump inhibitors; SBP, systolic blood pressure.